149 related articles for article (PubMed ID: 29385144)
61. Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study.
Egli-Gany D; Spaar Zographos A; Diebold J; Masserey Spicher V; Frey Tirri B; Heusser R; Dillner J; Petignat P; Sahli R; Low N;
BMC Cancer; 2019 Jan; 19(1):111. PubMed ID: 30700274
[TBL] [Abstract][Full Text] [Related]
62. Cervical Precancer and Cancer Risk by Human Papillomavirus Status and Cytologic Interpretation: Implications for Risk-Based Management.
Castle PE; Aslam S; Behrens C
Cancer Epidemiol Biomarkers Prev; 2016 Dec; 25(12):1595-1599. PubMed ID: 27587789
[TBL] [Abstract][Full Text] [Related]
63. A Low-Cost HPV Immunochromatographic Assay to Detect High-Grade Cervical Intraepithelial Neoplasia.
Mariano VS; Lorenzi AT; Scapulatempo-Neto C; Stein MD; Resende JC; Antoniazzi M; Villa LL; Levi JE; Longatto-Filho A; Fregnani JH
PLoS One; 2016; 11(10):e0164892. PubMed ID: 27764154
[TBL] [Abstract][Full Text] [Related]
64. Identification of promiscuous HPV16-derived T helper cell epitopes for therapeutic HPV vaccine design.
Grabowska AK; Kaufmann AM; Riemer AB
Int J Cancer; 2015 Jan; 136(1):212-24. PubMed ID: 24824905
[TBL] [Abstract][Full Text] [Related]
65. Antibody responses to HPV16 virus-like particles in women with cervical intraepithelial neoplasia infected with a variant HPV16.
Ellis JR; Etherington I; Galloway D; Luesley D; Young LS
Lancet; 1997 Apr; 349(9058):1069-70. PubMed ID: 9107250
[No Abstract] [Full Text] [Related]
66. Assessment of the effectiveness of HPV16/18 infection referred for colposcopy in cervical cancer screening in Northwest of China.
Zhang Q; Zhao M; Cao D; Wei X; Wang L; Li Y; Yang T; Zhao J; Pei M; Jia H; Cao S; Quan S; Yang X
J Med Virol; 2018 Jan; 90(1):165-171. PubMed ID: 28710863
[TBL] [Abstract][Full Text] [Related]
67. Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia.
Yang W; Song Y; Lu YL; Sun JZ; Wang HW
Immunology; 2013 Aug; 139(4):513-22. PubMed ID: 23521696
[TBL] [Abstract][Full Text] [Related]
68. Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens.
Trevisan A; Candeias JMG; Thomann P; Villa LL; Franco EL; Trottier H; The Ludwig-McGill Study Group
J Med Microbiol; 2020 Jul; 69(7):960-970. PubMed ID: 32510304
[No Abstract] [Full Text] [Related]
69. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe.
Tjalma WA; Fiander A; Reich O; Powell N; Nowakowski AM; Kirschner B; Koiss R; O'Leary J; Joura EA; Rosenlund M; Colau B; Schledermann D; Kukk K; Damaskou V; Repanti M; Vladareanu R; Kolomiets L; Savicheva A; Shipitsyna E; Ordi J; Molijn A; Quint W; Raillard A; Rosillon D; De Souza SC; Jenkins D; Holl K;
Int J Cancer; 2013 Feb; 132(4):854-67. PubMed ID: 22752992
[TBL] [Abstract][Full Text] [Related]
70. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6.
de Jong A; van Poelgeest MI; van der Hulst JM; Drijfhout JW; Fleuren GJ; Melief CJ; Kenter G; Offringa R; van der Burg SH
Cancer Res; 2004 Aug; 64(15):5449-55. PubMed ID: 15289354
[TBL] [Abstract][Full Text] [Related]
71. Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort.
Chen Y; Qiu X; Wang W; Li D; Wu A; Hong Z; Di W; Qiu L
BMC Infect Dis; 2020 Aug; 20(1):629. PubMed ID: 32842982
[TBL] [Abstract][Full Text] [Related]
72. Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial.
Monsonego J; Cox JT; Behrens C; Sandri M; Franco EL; Yap PS; Huh W
Gynecol Oncol; 2015 Apr; 137(1):47-54. PubMed ID: 25667973
[TBL] [Abstract][Full Text] [Related]
73. Human papilloma virus infection of uterine cervix and spectrum of cervical pathology in human immunodeficiency virus/AIDS.
Jain BB; Adhikary T; Sadhukhan PC; Nandi A
J Cancer Res Ther; 2021; 17(6):1462-1467. PubMed ID: 34916378
[TBL] [Abstract][Full Text] [Related]
74. Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16
Song F; Yan P; Huang X; Wang C; Qu X; Du H; Wu R
BMC Infect Dis; 2021 Apr; 21(1):400. PubMed ID: 33931022
[TBL] [Abstract][Full Text] [Related]
75. A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia.
Schiffman M; Rodriguez AC; Chen Z; Wacholder S; Herrero R; Hildesheim A; Desalle R; Befano B; Yu K; Safaeian M; Sherman ME; Morales J; Guillen D; Alfaro M; Hutchinson M; Solomon D; Castle PE; Burk RD
Cancer Res; 2010 Apr; 70(8):3159-69. PubMed ID: 20354192
[TBL] [Abstract][Full Text] [Related]
76. Cervicovaginal, oral, and serum IgG and IgA responses to human papillomavirus type 16 in women with cervical intraepithelial neoplasia.
Passmore JA; Marais DJ; Sampson C; Allan B; Parker N; Milner M; Denny L; Williamson AL
J Med Virol; 2007 Sep; 79(9):1375-80. PubMed ID: 17607771
[TBL] [Abstract][Full Text] [Related]
77. Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia.
Passmore JA; Milner M; Denny L; Sampson C; Marais DJ; Allan B; Gumbi PP; Hitzeroth II; Rybicki EP; Williamson AL
Immunology; 2006 Dec; 119(4):507-14. PubMed ID: 17026720
[TBL] [Abstract][Full Text] [Related]
78. HPV16-L1-specific antibody response is associated with clinical remission of high-risk HPV-positive early dysplastic lesions.
Mehlhorn G; Hautmann SK; Koch MC; Strehl JD; Hartmann A; Hilfrich R; Beckmann MW; Griesser H
Anticancer Res; 2014 Sep; 34(9):5127-32. PubMed ID: 25202103
[TBL] [Abstract][Full Text] [Related]
79. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Wheeler CM; Castellsagué X; Garland SM; Szarewski A; Paavonen J; Naud P; Salmerón J; Chow SN; Apter D; Kitchener H; Teixeira JC; Skinner SR; Jaisamrarn U; Limson G; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Harper DM; Huh W; Hardt K; Zahaf T; Descamps D; Struyf F; Dubin G; Lehtinen M;
Lancet Oncol; 2012 Jan; 13(1):100-10. PubMed ID: 22075170
[TBL] [Abstract][Full Text] [Related]
80. Association of genomic variants at the human leukocyte antigen locus with cervical cancer risk, HPV status and gene expression levels.
Ramachandran D; Schürmann P; Mao Q; Wang Y; Bretschneider LM; Speith LM; Hülse F; Enßen J; Bousset K; Jentschke M; Böhmer G; Strauß HG; Hirchenhain C; Schmidmayr M; Tarbiat J; Runnebaum I; Dürst M; Hein A; Koch M; Ruebner M; Ekici A; Beckmann MW; Fasching PA; Luyten A; Petry KU; Hillemanns P; Dörk T
Int J Cancer; 2020 Nov; 147(9):2458-2468. PubMed ID: 32580243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
